Cyclerion Therapeutics Stock
Cyclerion Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Regina Graul
- Employees
- 1
- Market cap
- $16 M
- IPO
- 18/03/2019
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate…
Cyclerion Therapeutics stock: price history
1D
+0.8%
1W
-0.4%
1M
+3.3%
6M
+5.7%
YTD
+245.6%
1Y
+75.5%
2Y
+80.6%
5Y
-92.4%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~7% weaker price swings than usual
Ask the agents about Cyclerion Therapeutics
Analyst assessment of Cyclerion Therapeutics
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
No current analyst ratings available.
Cyclerion Therapeutics stock metrics
P/E
-1.95
P/B
2.81
EV/EBITDA
-2.14
RETURN ON EQUITY
-34.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
67.1%
FLOAT SHARES
448,810
AVG. DAILY VOLUME (30D)
78,493
Insider transactions (SEC)
Graul Regina Margaret
Graul Regina Margaret
CHICKO RHONDA M.
Hecht Peter M
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cyclerion Therapeutics stock
What does Cyclerion Therapeutics do?
Cyclerion Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Regina Graul, the company employs around 1 people.
The IPO was on 18/03/2019; the stock trades on NASDAQ under the ticker CYCN.
When does Cyclerion Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -7% stronger than usual.
Does Cyclerion Therapeutics pay a dividend?
No, Cyclerion Therapeutics currently does not pay a dividend.
Which stocks are comparable to Cyclerion Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cyclerion Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cyclerion Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.